CARA
Income statement / Annual
Last year (2024), Cara Therapeutics, Inc.'s total revenue was $7.14 M,
a decrease of 65.96% from the previous year.
In 2024, Cara Therapeutics, Inc.'s net income was -$70.87 M.
See Cara Therapeutics, Inc.,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2024
|
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
| Period Ended |
12/31/2024 |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
12/31/2015 |
| Operating Revenue |
$7.14 M |
$20.97 M |
$41.87 M |
$23.03 M |
$135.08 M |
$19.89 M |
$13.47 M |
$911,000.00 |
$86,000.00 |
$3.80 M |
| Cost of Revenue |
$0.00
|
$6.17 M
|
$7.27 M
|
$1.55 M
|
$107.07 M
|
$113.16 M
|
$75.53 M
|
$48.52 M
|
$49.25 M
|
$21.22 M
|
| Gross Profit |
$7.14 M
|
$14.79 M
|
$34.60 M
|
$21.47 M
|
$28.01 M
|
-$93.28 M
|
-$62.06 M
|
-$47.61 M
|
-$49.17 M
|
-$17.42 M
|
| Gross Profit Ratio |
1
|
0.71
|
0.83
|
0.93
|
0.21
|
-4.69
|
-4.61
|
-52.26
|
-571.71
|
-4.58
|
| Research and Development Expenses |
$32.81 M
|
$108.51 M
|
$91.88 M
|
$82.70 M
|
$107.85 M
|
$113.82 M
|
$75.53 M
|
$48.52 M
|
$49.25 M
|
$21.22 M
|
| General & Administrative Expenses |
$26.53 M
|
$27.65 M
|
$30.26 M
|
$29.41 M
|
$21.75 M
|
$17.75 M
|
$15.32 M
|
$11.87 M
|
$9.23 M
|
$7.77 M
|
| Selling & Marketing Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General & Administrative Expenses |
$26.53 M
|
$27.65 M
|
$30.26 M
|
$29.41 M
|
$21.75 M
|
$17.75 M
|
$15.32 M
|
$11.87 M
|
$9.23 M
|
$7.77 M
|
| Other Expenses |
$6.19 M
|
$0.00
|
$2.06 M
|
$642,000.00
|
$97,000.00
|
$4.49 M
|
$2.98 M
|
$1.16 M
|
$652,000.00
|
$101,000.00
|
| Operating Expenses |
$65.52 M
|
$136.29 M
|
$122.14 M
|
$112.11 M
|
$129.70 M
|
$131.57 M
|
$90.85 M
|
$60.40 M
|
$58.49 M
|
$28.99 M
|
| Cost And Expenses |
$65.52 M
|
$142.46 M
|
$129.40 M
|
$112.11 M
|
$129.70 M
|
$131.57 M
|
$90.85 M
|
$60.40 M
|
$58.49 M
|
$28.99 M
|
| Interest Income |
$0.00
|
$0.00
|
$2.06 M
|
$603,000.00
|
$2.06 M
|
$4.49 M
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Interest Expense |
-$8.47 M
|
$604,000.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Depreciation & Amortization |
$0.00
|
$259,000.00
|
$1.67 M
|
$1.55 M
|
$1.01 M
|
$799,000.00
|
$370,000.00
|
$495,000.00
|
$1.47 M
|
$839,000.00
|
| EBITDA |
$0.00 |
-$117.65 M |
-$83.80 M |
-$88.19 M |
$5.59 M |
-$111.48 M |
-$77.01 M |
-$58.99 M |
-$56.94 M |
-$24.35 M |
| EBITDA Ratio |
0
|
-5.61
|
-2.09
|
-3.87
|
0.04
|
-5.62
|
-5.75
|
-65.3
|
-679.07
|
-6.62
|
| Operating Income Ratio |
-8.18
|
-5.79
|
-2.09
|
-3.87
|
0.04
|
-5.62
|
-5.75
|
-65.3
|
-679.07
|
-6.62
|
| Total Other Income/Expenses Net |
-$12.88 M
|
$2.98 M
|
$2.06 M
|
$642,000.00
|
$2.33 M
|
$4.49 M
|
$2.98 M
|
$1.16 M
|
$652,000.00
|
$101,000.00
|
| Income Before Tax |
-$71.27 M
|
-$118.51 M
|
-$85.47 M
|
-$88.44 M
|
$7.72 M
|
-$107.19 M
|
-$74.40 M
|
-$58.33 M
|
-$57.75 M
|
-$25.09 M
|
| Income Before Tax Ratio |
-9.99
|
-5.65
|
-2.04
|
-3.84
|
0.06
|
-5.39
|
-5.52
|
-64.03
|
-671.49
|
-6.6
|
| Income Tax Expense |
$398,000.00
|
$0.00
|
-$2.06 M
|
-$248,000.00
|
-$691,000.00
|
-$816,000.00
|
-$389,000.00
|
-$204,000.00
|
-$468,000.00
|
-$397,000.00
|
| Net Income |
-$70.87 M
|
-$118.51 M
|
-$83.41 M
|
-$88.19 M
|
$8.41 M
|
-$106.37 M
|
-$74.01 M
|
-$58.13 M
|
-$57.28 M
|
-$24.69 M
|
| Net Income Ratio |
-9.93
|
-5.65
|
-1.99
|
-3.83
|
0.06
|
-5.35
|
-5.5
|
-63.8
|
-666.05
|
-6.49
|
| EPS |
-0.0155 |
-2.19 |
-1.55 |
-1.74 |
0.18 |
-2.49 |
-2.06 |
-1.86 |
-2.1 |
-1 |
| EPS Diluted |
-0.0155 |
-2.19 |
-1.55 |
-1.74 |
0.18 |
-2.49 |
-2.06 |
-1.86 |
-2.1 |
-1 |
| Weighted Average Shares Out |
$4.56 B
|
$54.15 M
|
$53.65 M
|
$50.72 M
|
$47.41 M
|
$42.67 M
|
$35.89 M
|
$31.20 M
|
$27.28 M
|
$24.62 M
|
| Weighted Average Shares Out Diluted |
$4.56 B
|
$54.15 M
|
$53.65 M
|
$50.72 M
|
$47.92 M
|
$42.67 M
|
$35.89 M
|
$31.20 M
|
$27.28 M
|
$24.62 M
|
| Link |
|
|
|
|
|
|
|
|
|
|
